Formoterol/ beclometasone extrafine inhaler now an option for COPD

The dry powder inhaler Fostair NEXThaler (formoterol/beclometasone) has been approved to treat severe COPD, in addition to asthma.

Fostair NEXThaler is licensed for use in patients with severe COPD (FEV1 less than 50% of predicted normal). | SCIENCE PHOTO LIBRARY
Fostair NEXThaler is licensed for use in patients with severe COPD (FEV1 less than 50% of predicted normal). | SCIENCE PHOTO LIBRARY

Like the Fostair metered-dose inhaler, Fostair NEXThaler is suitable for COPD patients with an FEV1 less than 50% of predicted normal and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

The recommended adult dose is two inhalations twice daily.

Further information
View Fostair NEXThaler drug record 
Summary of Product Characteristics
Manufacturer: Chiesi

The NEXThaler device is a breath-actuated dry powder inhaler which delivers formoterol and beclometasone as extrafine particles to improve lung deposition. 

Prescribers should note that the beclometasone doses in Fostair products are not equivalent to those delivered by non-extrafine formulations. Owing to the difference in particle sizes, 250 microgram beclometasone administered via a standard inhaler is therapeutically equivalent to 100 microgram beclometasone in a Fostair product when given via the NEXThaler device or the Fostair metered dose inhaler.

Fostair NEXThaler was developed to be 'intuitive to use', according to the manufacturer, and utilises a dose counter that decreases only when a dose has been correctly inhaled.


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.